This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Topical corticosteroids

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Topical corticosteroids revolutionised the management of inflammatory skin disease when they were introduced in the 1950's. They are used as first-line or adjunctive treatment in several inflammatory dermatoses (1) (particularly beneficial for eczema and psoriasis), and have a place in the treatment of other dermatoses e.g. alopecia areata, keloid scars and non-infected granulomas.

  • in addition to the anti inflammatory property, topical corticosteroids also exert their effect through vasoconstrictive, anti-proliferative and immunosuppressive properties (1)
  • because they are not targeting the disease process, generally only symptomatic relief is obtained
  • rebound exacerbation of the condition may occur on cessation of the corticosteroid agent (2)

They are not beneficial in urticaria or pruritus of unknown cause and they exacerbate rosacea, acne and ulceration (2). Systemic side effects may be serious.

Topical corticosteroids come in a variety of strengths. A good rule is to use the least potent drug at the lowest strength possible for a therapeutic effect.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.